SCHEMBL20206207

SCHEMBL20206207

CC(=O)NCC(=O)N[C@H]1CCC(=O)NCC[C@@H](C(=O)NCC(N)=O)NC(=O)CNC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCN)NC1=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.40
▸ CTSG P08311 1/20 0.39
▸ MC4R P32245 2/20 0.39
▸ OPRM1 P35372 2/20 0.38
▸ OPRD1 P41143 2/20 0.38
▸ OPRK1 P41145 2/20 0.38
▸ SIRT2 Q8IXJ6 1/20 0.38
▸ SIRT1 Q96EB6 1/20 0.38
▸ SIRT3 Q9NTG7 1/20 0.38
▸ KDM1A O60341 1/20 0.38
▸ RCOR1 Q9UKL0 1/20 0.38
▸ MC1R Q01726 2/20 0.38
▸ ITGB3 P05106 1/20 0.38
▸ ITGAV P06756 1/20 0.38
▸ TBXA2R P21731 1/20 0.37
▸ AVPR1A P37288 1/20 0.37
▸ PDE4D Q08499 1/20 0.37
▸ PDE3A Q14432 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20206177 0.96 MC4R (0.40) CTSGMC4RSIRT2SIRT1SIRT3
SCHEMBL20206181 0.95 SIRT2 (0.41) MC4RSIRT2SIRT1SIRT3ITGB3
SCHEMBL20206174 0.93 OPRM1 (0.44) OPRM1OPRD1OPRK1
SCHEMBL20206279 0.92 SIRT2 (0.42) CTSGMC4RSIRT2SIRT1SIRT3
SCHEMBL20206278 0.92 MEN1 (0.40) CTSGMC4ROPRM1OPRD1OPRK1
SCHEMBL20206246 0.91 CTSG (0.46) CTSGMC4RSIRT2SIRT1SIRT3
SCHEMBL20206173 0.88 TSLP (0.39) CTSGMC4ROPRM1OPRD1OPRK1
SCHEMBL20362936 0.86 TSLP (0.39) CTSGMC4ROPRM1OPRD1OPRK1
SCHEMBL21392252 0.85 OPRM1 (0.46) OPRM1OPRD1OPRK1SIRT2SIRT1
SCHEMBL22606201 0.85 OPRM1 (0.43) OPRM1OPRD1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11286280-B2 Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy PALATIN TECHNOLOGIES, INC. (US) 2022-03-29 — — US disclosed
US-20200339631-A1 Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy PALATIN TECHNOLOGIES INC (US) 2020-10-29 — — US disclosed
US-10711039-B2 Melanocortin receptor-specific peptide with C-terminal naphthylalanine PALATIN TECHNOLOGIES, INC. (US) 2020-07-14 — — US disclosed
US-10017539-B2 Melanocortin-1 receptor-specific cyclic hexapeptides PALATIN TECHNOLOGIES, INC. (US) 2018-07-10 — — US disclosed
US-20180148478-A1 Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine PALATIN TECHNOLOGIES INC (US) 2018-05-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711039-B2 Melanocortin receptor-specific peptide with C-terminal naphthylalanine MC1R, MC3R, MC4R KEAP1 2138/4885CTSG 2450/4885MC4R 3/4885
US-11286280-B2 Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy MC3R, MC1R, MC2R KEAP1 2202/4885CTSG 844/4885MC4R 6/4885
US-10017539-B2 Melanocortin-1 receptor-specific cyclic hexapeptides MC1R, MC3R, MC5R KEAP1 1972/4885CTSG 2062/4885MC4R 4/4885
US-20200339631-A1 Melanocortin-1 Receptor-Specific Peptides for Cytokine Storm and Inflammation Therapy MC3R, MC1R, MC2R KEAP1 2202/4885CTSG 844/4885MC4R 6/4885
US-20180148478-A1 Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine MC1R, MC3R, MC4R KEAP1 2138/4885CTSG 2450/4885MC4R 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback